Trial Profile
Vorinostat and Carboplatin or Vorinostat and Paclitaxel in Patients With Advanced Solid Tumors: A Pharmacokinetic and Pharmacodynamic Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Carboplatin; Paclitaxel
- Indications Solid tumours
- Focus Pharmacokinetics
- 07 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 04 Jun 2013 Primary endpoint 'Peak-drug-concentration' has been met.
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.